205 related articles for article (PubMed ID: 34625792)
1. Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphoma.
Pighi C; Cheong TC; Compagno M; Patrucco E; Arigoni M; Olivero M; Wang Q; López C; Bernhart SH; Grande BM; Poggio T; Langellotto F; Bonello L; Dall'Olio R; Martínez-Martín S; Molinaro L; Francia di Celle P; Whitfield JR; Soucek L; Voena C; Calogero RA; Morin RD; Staudt LM; Siebert R; Zamò A; Chiarle R
Blood Adv; 2021 Dec; 5(23):5239-5257. PubMed ID: 34625792
[TBL] [Abstract][Full Text] [Related]
2. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas.
Duan S; Cermak L; Pagan JK; Rossi M; Martinengo C; di Celle PF; Chapuy B; Shipp M; Chiarle R; Pagano M
Nature; 2012 Jan; 481(7379):90-3. PubMed ID: 22113614
[TBL] [Abstract][Full Text] [Related]
3. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations.
Akpa CA; Kleo K; Lenze D; Oker E; Dimitrova L; Hummel M
PLoS One; 2019; 14(8):e0220681. PubMed ID: 31419226
[TBL] [Abstract][Full Text] [Related]
4. Novel Biological Insights and New Developments in Management of Burkitt Lymphoma and High-Grade B-Cell Lymphoma.
Lap CJ; Nassereddine S; Dunleavy K
Curr Treat Options Oncol; 2021 Jun; 22(7):60. PubMed ID: 34097157
[TBL] [Abstract][Full Text] [Related]
5. FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease.
Schneider C; Kon N; Amadori L; Shen Q; Schwartz FH; Tischler B; Bossennec M; Dominguez-Sola D; Bhagat G; Gu W; Basso K; Dalla-Favera R
Blood; 2016 Aug; 128(5):660-6. PubMed ID: 27166359
[TBL] [Abstract][Full Text] [Related]
6. Genetic features of precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement.
Yoshida M; Tomizawa D; Yoshimura S; Osumi T; Nakabayashi K; Ogata-Kawata H; Ishiwata K; Sato-Otsubo A; Kimura Y; Ito S; Matsumoto K; Deguchi T; Kiyokawa N; Yoshioka T; Hata K; Kato M
Cancer Rep (Hoboken); 2022 Jul; 5(7):e1545. PubMed ID: 34472720
[TBL] [Abstract][Full Text] [Related]
7. Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.
Pillai RK; Sathanoori M; Van Oss SB; Swerdlow SH
Am J Surg Pathol; 2013 Mar; 37(3):323-32. PubMed ID: 23348205
[TBL] [Abstract][Full Text] [Related]
8. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.
Aukema SM; Kreuz M; Kohler CW; Rosolowski M; Hasenclever D; Hummel M; Küppers R; Lenze D; Ott G; Pott C; Richter J; Rosenwald A; Szczepanowski M; Schwaenen C; Stein H; Trautmann H; Wessendorf S; Trümper L; Loeffler M; Spang R; Kluin PM; Klapper W; Siebert R;
Haematologica; 2014 Apr; 99(4):726-35. PubMed ID: 24179151
[TBL] [Abstract][Full Text] [Related]
9. Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation.
Sun D; Stopka-Farooqui U; Barry S; Aksoy E; Parsonage G; Vossenkämper A; Capasso M; Wan X; Norris S; Marshall JL; Clear A; Gribben J; MacDonald TT; Buckley CD; Korbonits M; Haworth O
Cell Rep; 2019 Apr; 27(5):1461-1471.e4. PubMed ID: 31042473
[TBL] [Abstract][Full Text] [Related]
10. EBV
Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S
Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146
[TBL] [Abstract][Full Text] [Related]
11. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
12. The oncogenic microRNA-21 inhibits the tumor suppressive activity of FBXO11 to promote tumorigenesis.
Yang CH; Pfeffer SR; Sims M; Yue J; Wang Y; Linga VG; Paulus E; Davidoff AM; Pfeffer LM
J Biol Chem; 2015 Mar; 290(10):6037-46. PubMed ID: 25589783
[TBL] [Abstract][Full Text] [Related]
13. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
14. Chronic psychological stress impairs germinal center response by repressing miR-155.
Sun W; Zhang L; Lin L; Wang W; Ge Y; Liu Y; Yang B; Hou J; Cheng X; Chen X; Wang Z
Brain Behav Immun; 2019 Feb; 76():48-60. PubMed ID: 30414952
[TBL] [Abstract][Full Text] [Related]
15. Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and/or BCL6 Rearrangements.
Alsharif R; Dunleavy K
Hematol Oncol Clin North Am; 2019 Aug; 33(4):587-596. PubMed ID: 31229156
[TBL] [Abstract][Full Text] [Related]
16. Constitutional 2p16.3 deletion including MSH6 and FBXO11 in a boy with developmental delay and diffuse large B-cell lymphoma.
van Engelen N; van Dijk F; Waanders E; Buijs A; Vermeulen MA; Loeffen JLC; Kuiper RP; Jongmans MCJ
Fam Cancer; 2021 Oct; 20(4):349-354. PubMed ID: 33811277
[TBL] [Abstract][Full Text] [Related]
17. Double-Hit Lymphoma (MYC and BCL6) with Involvement of Skull and Adnexal Lesions: A Case Report and a Review of the Literature.
Minhas H; Abdelmalek C; Khan M; O'Donnell JE; Gotlieb V; Wang JC
Am J Case Rep; 2018 Aug; 19():1035-1041. PubMed ID: 30158513
[TBL] [Abstract][Full Text] [Related]
18. The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.
Hüttl KS; Staiger AM; Richter J; Ott MM; Kalmbach S; Klapper W; Biesdorf AS; Trümper L; Rosenwald A; Ziepert M; Horn H; Ott G
Virchows Arch; 2021 Sep; 479(3):575-583. PubMed ID: 33655392
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Lethal Screen Demonstrates That a JAK2 Inhibitor Suppresses a BCL6-dependent IL10RA/JAK2/STAT3 Pathway in High Grade B-cell Lymphoma.
Beck D; Zobel J; Barber R; Evans S; Lezina L; Allchin RL; Blades M; Elliott R; Lord CJ; Ashworth A; Porter AC; Wagner SD
J Biol Chem; 2016 Aug; 291(32):16686-98. PubMed ID: 27268052
[TBL] [Abstract][Full Text] [Related]
20. Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.
Haralambieva E; Boerma EJ; van Imhoff GW; Rosati S; Schuuring E; Müller-Hermelink HK; Kluin PM; Ott G
Am J Surg Pathol; 2005 Aug; 29(8):1086-94. PubMed ID: 16006805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
